Judah Frommer
Stock Analyst at Morgan Stanley
(3.94)
# 585
Out of 4,964 analysts
180
Total ratings
60.31%
Success rate
6.52%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Initiates: Overweight | $18 | $7.28 | +147.25% | 1 | Aug 21, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Equal-Weight | $25 → $26 | $27.52 | -5.52% | 2 | Jul 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Overweight | $46 → $43 | $21.93 | +96.08% | 2 | May 9, 2025 | |
| ABVX ABIVAX Société Anonyme | Assumes: Equal-Weight | $12 | $77.46 | -84.51% | 1 | Mar 20, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $22 → $24 | $8.97 | +167.56% | 2 | Mar 14, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | $31 → $22 | $31.44 | -30.03% | 3 | Feb 14, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $6.74 | -10.98% | 2 | Jan 13, 2025 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $68.49 | +54.77% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $11.32 | +209.19% | 1 | Oct 8, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $2.06 | +531.07% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $3 | $2.35 | +27.66% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $2.96 | +1,251.35% | 8 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.51 | +760.93% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $45.27 | -33.73% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $18.87 | +21.89% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $49.31 | +1.41% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $18.06 | +680.73% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $4.74 | +89.87% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $24.70 | -10.93% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $5.71 | +22.59% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $6.41 | +24.80% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $25.04 | +83.71% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.15 | +225.58% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $15.55 | +253.70% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $128.32 | -64.15% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $101.86 | -51.89% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $941.58 | -60.70% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $77.50 | -60.00% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $79.33 | -4.20% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $112.35 | +61.99% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $111.80 | -4.29% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $130.16 | -27.01% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $19.68 | -8.54% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $140.49 | -17.43% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $95.32 | -60.13% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $145.31 | -84.86% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $70.14 | -50.10% | 9 | Apr 29, 2020 |
Trevi Therapeutics
Aug 21, 2025
Initiates: Overweight
Price Target: $18
Current: $7.28
Upside: +147.25%
Apellis Pharmaceuticals
Jul 2, 2025
Maintains: Equal-Weight
Price Target: $25 → $26
Current: $27.52
Upside: -5.52%
Celldex Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $46 → $43
Current: $21.93
Upside: +96.08%
ABIVAX Société Anonyme
Mar 20, 2025
Assumes: Equal-Weight
Price Target: $12
Current: $77.46
Upside: -84.51%
REGENXBIO
Mar 14, 2025
Maintains: Overweight
Price Target: $22 → $24
Current: $8.97
Upside: +167.56%
Galapagos NV
Feb 14, 2025
Downgrades: Underweight
Price Target: $31 → $22
Current: $31.44
Upside: -30.03%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $6.74
Upside: -10.98%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $68.49
Upside: +54.77%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $11.32
Upside: +209.19%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $2.06
Upside: +531.07%
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $2.35
Upside: +27.66%
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $2.96
Upside: +1,251.35%
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.51
Upside: +760.93%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $45.27
Upside: -33.73%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $18.87
Upside: +21.89%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $49.31
Upside: +1.41%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $18.06
Upside: +680.73%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $4.74
Upside: +89.87%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $24.70
Upside: -10.93%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $5.71
Upside: +22.59%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $6.41
Upside: +24.80%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $25.04
Upside: +83.71%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.15
Upside: +225.58%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $15.55
Upside: +253.70%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $128.32
Upside: -64.15%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $101.86
Upside: -51.89%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $941.58
Upside: -60.70%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $77.50
Upside: -60.00%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $79.33
Upside: -4.20%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $112.35
Upside: +61.99%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $111.80
Upside: -4.29%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $130.16
Upside: -27.01%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $19.68
Upside: -8.54%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $140.49
Upside: -17.43%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $95.32
Upside: -60.13%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $145.31
Upside: -84.86%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $70.14
Upside: -50.10%